CHECKMATE 040: EFFICACY, HEPATIC SAFETY, AND BIOMARKERS OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Sangro, Bruno [1 ,2 ]
Hsu, Chiun [3 ]
Kang, Yoon-Koo [4 ]
Kim, Tae-You [5 ]
El-Khoueiry, Anthony [6 ]
Santoro, Armando [7 ]
Melero, Ignacio [8 ]
Kudo, Masatoshi [9 ]
Hou, Ming-Mo [10 ]
Pena, Ana Matilla [11 ]
Tovoli, Francesco [12 ]
Knox, Jennifer J. [13 ]
He, Aiwu Ruth [14 ]
El-Rayes, Bassel [15 ]
Acosta, Mirelis Rivera [16 ]
Lim, Ho-Yeong [17 ]
Neely, Jaclyn [18 ]
Zhao, Huanyu [18 ]
Anderson, Jeffrey [18 ]
Yau, Thomas [19 ]
机构：
[1] Clin Univ Navarra, Idisna, Pamplona, Spain
[2] Ciberehd, Madrid, Spain
[3] Natl Taiwan Univ Hosp, Taipei, Taiwan
[4] Univ Ulsan, Asan Med Ctr, Ulsan, South Korea
[5] Seoul Natl Univ, Seoul, South Korea
[6] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[7] Humanitas Univ, Humanitas Clin & Res Ctr, Rozzano, Italy
[8] Univ Navarra, Pamplona, Spain
[9] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Higashiosaka, Osaka, Japan
[10] Chang Gung Mem Hosp, Taipei, Taiwan
[11] Hosp Gen Univ Gregorio Maranon, Serv Digest, Madrid, Spain
[12] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[13] Princess Margaret Canc Ctr, Toronto, ON, Canada
[14] Georgetown Univ Hosp, Washington, DC 20007 USA
[15] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[16] Fdn Invest, San Juan, PR USA
[17] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[18] Bristol Myers Squibb, New York, NY USA
[19] Univ Hong Kong, Hong Kong, Peoples R China
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
200
引用
收藏
页码：131A / 132A
页数：2
相关论文
共 50 条
  • [31] CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
    Janjigian, Yelena Y.
    Bendell, Johanna
    Calvo, Emiliano
    Kim, Joseph W.
    Ascierto, Paolo A.
    Sharma, Padmanee
    Ott, Patrick A.
    Peltola, Katriina
    Jaeger, Dirk
    Evans, Jeffry
    de Braud, Filippo
    Chau, Ian
    Harbison, Christopher T.
    Dorange, Cecile
    Tschaika, Marina
    Le, Dung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2836 - +
  • [32] Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
    Melero, I.
    Sangro, B.
    Yau, T.
    Hsu, C.
    Kudo, M.
    Crocenzi, T.
    Kim, T-Y.
    Choo, S-P.
    Trojan, J.
    Meyer, T.
    Welling, T. H., III
    Yeo, W.
    Chopra, A.
    Anderson, J.
    Dela Cruz, C.
    Lang, L.
    Neely, J.
    El-Khoueiry, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204)
    Tawbi, Hussein
    Forsyth, Peter
    Hodi, F. Stephen
    Lao, Christopher
    Moschos, Stergios
    Hamid, Omid
    Atkins, Michael B.
    Lewis, Karl
    Thomas, Reena P.
    Glaspy, John A.
    Jang, Sekwon
    Algazi, Alain
    Khushalani, Nikhil I.
    Postow, Michael A.
    Pavlick, Anna C.
    Ernstoff, Marc
    Reardon, David A.
    Balogh, Agnes
    Rizzo, Jasmine
    Margolin, Kim
    BRITISH JOURNAL OF CANCER, 2019, 121 : 20 - 20
  • [34] Safety and efficacy of nivolumab plus ipilimumab (NIVO plus IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.
    Emamekhoo, Hamid
    Olsen, Mark
    Carthon, Bradley Curtis
    Drakaki, Alexandra
    Percent, Ivor John
    Molina, Ana M.
    Cho, Daniel C.
    Bendell, Johanna C.
    Gordan, Lucio N.
    Kalebasty, Arash Rezazadeh
    George, Daniel J.
    Hutson, Thomas E.
    Lee, Richard J.
    Young, Tina C.
    Johansen, Jennifer
    Tykodi, Scott S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.
    Emamekhoo, Hamid
    Olsen, Mark R.
    Carthon, Bradley Curtis
    Drakaki, Alexandra
    Percent, Ivor John
    Molina, Ana M.
    Cho, Daniel C.
    Bendell, Johanna C.
    Gordan, Lucio N.
    Kalebasty, Arash Rezazadeh
    George, Daniel J.
    Hutson, Thomas E.
    Arrowsmith, Edward
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    Leung, David
    Tykodi, Scott S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.
    Tykodi, Scott S.
    Gordan, Lucio N.
    Alter, Robert S.
    Arrowsmith, Edward
    Harrison, Michael Roger
    Percent, Ivor John
    Singal, Rakesh
    Van Veldhuizen, Peter J.
    George, Daniel J.
    Hutson, Thomas E.
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    Kalebasty, Arash Rezazadeh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [37] Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma
    LaPelusa, Michael
    Chamseddine, Shadi
    Cao, Hop Sanderson Tran
    Xiao, Lianchun
    Hasanov, Elshad
    Bhosale, Priya
    Amin, Hesham M.
    Mohamed, Yehia I.
    Gok Yavuz, Betul
    Sakr, Yara
    Xu, Li
    Hu, Ian
    Lee, Sunyoung S.
    Sakamuri, Divya
    Jindal, Sonali
    Nguyen, Van
    Curran, Michael A.
    Sun, Ryan
    Rashid, Asif
    Duda, Dan Gabriel
    Sharma, Padmanee
    Qayyum, Aliya
    Kaseb, Ahmed Omar
    ONCOLOGY, 2024,
  • [38] Nivolumab in Patients with Child-Pugh B Advanced Hepatocellular Carcinoma (aHCC) in the CheckMate-040 Study
    Kudo, Masatoshi
    Matilla, Ana M.
    Santoro, Armando
    Melero, Ignacio
    Cubillo Gracian, Antonio
    Rivera Acosta, Mirelis
    Choo, Su Pin
    El-Khoueiry, Anthony
    Kuromatsu, Ryoko
    El Rayes, Bassel
    Numata, Kazushi
    Itoh, Yoshito
    Di Costanzo, Francesco
    Crysler, Oxana
    Reig, Maria
    Shen, Yun
    Neely, Jaclyn
    Dela Cruz, Christine
    Baccan, Carlos
    Sangro, Bruno
    HEPATOLOGY, 2018, 68 (06) : 1445A - 1446A
  • [39] Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038
    Ribas, Antoni
    Martin-Algarra, Salvador
    Bhatia, Shailender
    Hwu, Wen-Jen
    Slingluff, Craig L.
    Sharfman, William H.
    Hodi, F. Stephen
    Urba, Walter J.
    Luke, Jason J.
    Haanen, John B.
    Callahan, Margaret K.
    Wolchok, Jedd D.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Young, Tina C.
    Qureshi, Anila
    Horak, Christine E.
    CANCER RESEARCH, 2017, 77
  • [40] CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC
    Antonia, Scott J.
    Gettinger, Scott N.
    Goldman, Jonathan
    Brahmer, Julie
    Borghaei, Hossein
    Chow, Laura Q.
    Ready, Neal E.
    Gerber, David E.
    Juergens, Rosalyn
    Shepherd, Frances
    Laurie, Scott A.
    Young, Tina
    Geese, William J.
    Agrawal, Shruti
    Li, Xuemei
    Hellmann, Matthew D.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S250 - S251
12345